BioMarin turns to ex-Roche dealmaker James Sabry to build ‘next version’ of 27-year-old company
SAN FRANCISCO — Not many biotechs survive beyond 25 years, let alone get multiple drugs approved and turn a profit. BioMarin Pharmaceutical has done all